Pfizer and BioNTech
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
August 30, 2023 10:00 ET | BioNTech SE
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical data...
Mordor Intelligence Logo_Comp.png
Short-Acting Insulin Market Revenues to Reach USD 8.29 Billion by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
August 18, 2023 09:30 ET | Mordor Intelligence
Hyderabad, Aug. 18, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Short-Acting Insulin Market Report (2023-2028)," the market is estimated at USD 6.99 billion in 2023....
Another Medicine to
Another Medicine to Stop Migraine in its Tracks – Zavzpret™ is Now Available, but Where will Neurologists use it?
August 17, 2023 14:57 ET | Spherix Global Insights
Exton, Pennsylvania, Aug. 17, 2023 (GLOBE NEWSWIRE) -- In February 2023, Pfizer published their positive Phase 3 clinical trial results for zavegepant (new brand name, Zavzpret™). At the time,...
Dyadic Logo Current.jpg
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
July 24, 2023 08:30 ET | Dyadic International, Inc.
Dosing of patients completed at the end of FebruaryData Safety Monitoring Board conducted analysis of Day 29 data No major vaccine-related safety concerns for either of the two dose levelsNo Serious...
Pfizer’s Litfulo Poi
Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata
July 11, 2023 09:58 ET | Spherix Global Insights
Exton, Pennsylvania, July 11, 2023 (GLOBE NEWSWIRE) -- In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia...
Mordor Intelligence Logo_Comp.png
Middle East and Africa Human Insulin Market is anticipated to register a CAGR of greater than 4% during 2023 – 2028 - Market Size, Share, Forecasts, and Trends Analysis Report by Mordor Intelligence.
April 05, 2023 09:00 ET | Mordor Intelligence
Hyderabad, April 05, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Middle East and Africa Human Insulin Market - (2023 – 2028),” the market is expected to register a...
Efficacy of COVID-19 Vaccines against Severe Illness and Death Reviewed in the Journal of American Physicians and Surgeons (AAPS)
March 21, 2023 11:47 ET | Association of American Physicians and Surgeons
TUCSON, Ariz., March 21, 2023 (GLOBE NEWSWIRE) -- The current medical narrative for promoting COVID-19 vaccination is to prevent severe illness and death, replacing the earlier claim that it...
logo-alt.png
Vitamin D Market is estimated to be US$ 3.08 billion by 2030 with a CAGR of 7.5% during the forecast period - By PMI
March 06, 2023 09:08 ET | PMI
Covina, March 06, 2023 (GLOBE NEWSWIRE) -- “According to the latest research study, the demand of Vitamin-D Market accounted for US$ 1.50 billion in 2020 and is estimated to be US$ 3.08 billion by...
2023 International Top-Down Proteomics Symposium Image LG.jpg
The Consortium for Top-Down Proteomics Announces the 2nd International Top-Down Proteomics Symposium, October 3-5, 2023, in Chicago, IL
March 01, 2023 10:17 ET | Consortium for Top-Down Proteomics
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- The Consortium for Top-Down Proteomics today announced the 2nd International Top-Down Proteomics Symposium, which will be held in Chicago, IL...
logo.png
Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease
February 07, 2023 07:05 ET | Arch Biopartners
TORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of...